JAL2 Antibody

Overview of JAK2 and Its Antibodies

JAK2 is a key mediator in cytokine receptor signaling, influencing processes such as cell proliferation, immune response, and erythropoiesis . Antibodies targeting JAK2 are essential tools for studying its activation, localization, and role in diseases like myeloproliferative neoplasms and autoimmune disorders .

Key JAK2 Antibodies and Their Applications

The table below summarizes commercially available JAK2 antibodies, their specifications, and applications:

Mechanistic Insights

• JAK2 phosphorylates STAT transcription factors (e.g., STAT5) upon cytokine stimulation, enabling nuclear translocation and gene activation .

• In rheumatoid arthritis models, JAK2-specific antibodies (e.g., those developed in ) reveal its overexpression in inflammatory cells, supporting its role in autoimmune pathogenesis .

Therapeutic Development

• A monoclonal antibody targeting mutant CALR in myelofibrosis (MF) showed promise in preclinical studies, with Phase I trials planned .

• JAK2 inhibitors (e.g., AZD1480) synergize with antibodies to suppress oncogenic signaling in prostate cancer .

Technical Considerations

• Phospho-Specific Antibodies: Antibodies like #3771 (Cell Signaling Technology) are critical for studying JAK2 activation dynamics, as autophosphorylation at Tyr1007/1008 is required for kinase activity .

• Cross-Reactivity: Some antibodies (e.g., Santa Cruz’s C-10) exhibit broad species reactivity, enabling comparative studies across models .

Challenges and Future Directions

• Specificity: Polyclonal antibodies may cross-react with JAK1 or JAK3 without careful validation .

• Clinical Translation: While CALR-targeted antibodies advance for MF, JAK2-positive diseases require novel approaches, such as degradation-inducing therapies .